An experimental drug that depletes the body of a protein that helps anchor damaging deposits of amyloid protein in tissues may provide a new therapeutic approach for amyloidosis and other disorders (such as Alzheimer disease) in which amyloid is present, according to new findings in the May 16 issue of Nature.
In amyloidosis, abnormally folded protein is deposited as insoluble fibrils that lead to tissue damage and disease. Another protein, serum amyloid P component (SAP), binds to amyloid fibrils and makes them particularly resistant to degradation by the body.
Stephenson J. Eroding Amyloid Deposits. JAMA. 2002;287(22):2937. doi:10.1001/jama.287.22.2937